|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 2 (January 15), 2000:
pp. 410-415
Effect of short-term interferon therapy on the outcome of
subsequent HLA-identical sibling bone marrow transplantation for
chronic myelogenous leukemia: an analysis from the International Bone
Marrow Transplant Registry
Sergio Giralt,
Richard Szydlo,
John M. Goldman,
Judy Veum-Stone,
James C. Biggs,
Roger H. Herzig,
John P. Klein,
Philip B. McGlave,
Gary Schiller,
Robert Peter Gale,
Philip A. Rowlings, and
Mary M. Horowitz
From the International Bone Marrow Transplant Registry, Health
Policy Institute, Medical College of Wisconsin, Milwaukee, WI; MD
Anderson Cancer Center, The University of Texas, Houston, TX; Imperial
College School of Medicine, Hammersmith Hospital, London, United
Kingdom; Department of Medicine, St Vincent Hospital, Sydney,
Australia; James Graham Brown Cancer Center, University of Louisville,
Louisville, KY; University of Minnesota Hospital and Clinics,
Minneapolis, MN; UCLA Center for Health Sciences, Los Angeles, CA; and
the Division of Bone Marrow and Stem Cell Transplantation, Salick
Health Care, Inc, Los Angeles, CA.
Allogeneic bone marrow transplantation (BMT) is the only curative
therapy for chronic myelogenous leukemia (CML), though several studies
indicate that prolonged survival can result from interferon- (IFN-) treatment. IFN- is now often used as initial therapy for
CML, before donor availability is known. Because identifying potential
donors can take several weeks to months, it is important to know
whether IFN- adversely affects outcome of a subsequent BMT. If it
does, initiation of IFN- therapy might be delayed until donor
availability is determined and avoided in patients for whom BMT is
planned. We studied 873 patients who received HLA-identical sibling BMT
for chronic-phase CML in 153 centers participating in the International
Bone Marrow Transplant Registry. The object was to compare outcome in
the 664 who received only hydroxyurea before BMT with outcome in the
209 who received IFN- with or without hydroxyurea. The median
duration of IFN- therapy was 2 months (range, 1 to 39 months). Cox
proportional hazards analysis was used to compare engraftment,
graft-versus-host disease (GVHD), nonrelapse mortality, relapse,
survival, and leukemia-free survival after adjustment for other
prognostic variables. We found a higher risk of nonengraftment among
patients given IFN- than among those given hydroxyurea alone (2%
versus 0.2%; P = 0.01). Patients who received IFN- had
a lower risk of relapse (relative risk, 0.17; 95% confidence interval,
0.04-0.70). Probabilities of GVHD, nonrelapse mortality, survival, and
leukemia-free survival were similar in the two treatment groups. These
results suggest that a short course of IFN- does not adversely
affect survival after a subsequent HLA-identical sibling BMT for
chronic-phase CML.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. M. Stone
Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach
Oncologist,
June 1, 2004;
9(3):
259 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Cwynarski, I. A. G. Roberts, S. Iacobelli, A. van Biezen, R. Brand, A. Devergie, J. M. Vossen, M. Aljurf, W. Arcese, F. Locatelli, et al.
Stem cell transplantation for chronic myeloid leukemia in children
Blood,
August 15, 2003;
102(4):
1224 - 1231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich
Chronic Myelogenous Leukemia
Hematology,
January 1, 2002;
2002(1):
111 - 135.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. J. Lee, J. P. Klein, C. Anasetti, J. H. Antin, F. R. Loberiza, B. J. Bolwell, C. F. LeMaistre, M. R. Litzow, D. Marks, E. K. Waller, et al.
The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase
Blood,
December 1, 2001;
98(12):
3205 - 3211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Druker, C. L. Sawyers, R. Capdeville, J. M. Ford, M. Baccarani, and J. M. Goldman
Chronic Myelogenous Leukemia
Hematology,
January 1, 2001;
2001(1):
87 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
